US Patent

US12370189 — Pharmaceutical formulation

Formulation · Assigned to RB Health US LLC · Expires 2036-10-11 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical formulation that includes guaifenesin, naproxen, and at least one additional active ingredient selected from an antitussive, decongestant, or antihistamine.

USPTO Abstract

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of guaifenesin, naproxen and at least one further active which is selected to be an antitussive, a decongestant or an antihistamine.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

Patent Metadata

Patent number: US12370189
Jurisdiction: US
Classification: Formulation
Expires: 2036-10-11
Drug substance claim: No
Drug product claim: Yes
Assignee: RB Health US LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.